Havana, Jan 9 (Prensa Latina) Cuban Finlay Vaccines Institute and the Pasteur Institute of Iran signed a collaboration agreement here to complement the clinical evidence of the anti-Covid-19 vaccine candidate from the Caribbean island, Soberana02.
In its official Twitter account, the Cuban entity explained that ‘this synergy will allow faster progress in immunization against the SARS-CoV-2 virus in both countries.’
For its part, the BioCubaFarma business group also highlighted the commitment to cooperation between both nations.
‘The Pasteur Institute of Iran has a long history of collaboration with BioCubaFarma. Today the ties of friendship between our two countries are strengthened with a new agreement related to the Sovereign Vaccine of the Finlay Institute against Covid-19’, said the entity.
Soberana 02 began its second phase of clinical trials on December 22 when the first volunteers received immunization and thus became the first Latin American drug to reach that stage.
On previous days and, exclusively with Prensa Latina, the director of the Finlay Institute, Doctor of Science Vicente Vérez, explained that they were preparing to carry out efficacy studies of said drug abroad.
He specified that, after phase II of clinical investigations, the third stage of the trials will begin, in which they foresee the evaluation of efficacy both in the Caribbean country and abroad.
The candidate is a conjugate vaccine, in which the virus antigen, the receptor-binding domain (RBD), is chemically bound to tetanus toxoid.
According to Vérez, the drug has two formulations and the second of them was highly effective in animals, as it provoked a very powerful immune response from the first week of its first dose.
It also induces a long-lasting memory in the immune response that, in addition to producing antibodies, makes them last.
The Finlay also developed the Sovereign 01 candidate, whose phase I clinical trial was scheduled to conclude in late 2020.
In addition, the largest of the Antilles has two other candidates against Covid-19, prepared at the Center for Genetic Engineering and Biotechnology: Abdala and Mambisa. The latter will be nasally applied.